Disease · MONDO_0005098
stroke disorder
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. stroke disorder. Diseases, record MONDO_0005098. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005098
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Acute Cerebrovascular Accident, Acute Cerebrovascular Accidents, Acute Stroke, Acute Strokes, Apoplexy, Apoplexy, Cerebrovascular, Brain Vascular Accident, Brain Vascular Accidents, CVA, CVA (Cerebrovascular Accident), CVA (cerebral vascular accident), CVA - Cerebrovascular accident unspecified, CVAs (Cerebrovascular Accident), Cerebral Stroke, Cerebral Strokes, Cerebral vascular events, Cerebrovascular Accident, Acute, Cerebrovascular Accidents, Cerebrovascular Accidents, Acute, Cerebrovascular Apoplexy, Cerebrovascular Apoplexya, Cerebrovascular Stroke, Cerebrovascular Strokes, Cerebrovascular accident (disorder), Cerebrovascular accident (disorder) [Ambiguous], Stroke NOS, Stroke NOS (disorder), Stroke and cerebrovascular accident unspecified, Stroke and cerebrovascular accident unspecified (disorder), Stroke, Acute, Stroke, Cerebral, Stroke, Cerebrovascular, Stroke/CVA - undefined, Strokes, Strokes, Acute, Strokes, Cerebral, Strokes, Cerebrovascular, Vascular Accident, Brain, Vascular Accidents, Brain, cerebrovascular accident, cerebrovascular accident, (CVA), ischemic stroke, stroke, stroke syndrome, syndrome, stroke, undetermined stroke
- Open Targets
- Highest stage of its drugs
- Approval, for 45 of its 228 drugs, from DailyMed, EMA Human Drugs and TTD
- Open Targets
Drugs228
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ASPIRIN | CHEMBL25 | Small molecule | Approval | DailyMed | 37 | 30 | 30 | Drugs and targets |
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Approval | EMA Human Drugs | 49 | 22 | 21 | Drugs and targets |
| ALTEPLASE | CHEMBL1201593 | Enzyme | Approval | DailyMed | 22 | 21 | 14 | Drugs and targets |
| APIXABAN | CHEMBL231779 | Small molecule | Approval | DailyMed and EMA Human Drugs | 20 | 16 | 15 | Drugs and targets |
| RIVAROXABAN | CHEMBL198362 | Small molecule | Approval | EMA Human Drugs | 15 | 12 | 11 | Drugs and targets |
| TICAGRELOR | CHEMBL398435 | Small molecule | Approval | DailyMed | 11 | 10 | 10 | Drugs and targets |
| EDOXABAN | CHEMBL1269025 | Small molecule | Approval | EMA Human Drugs | 9 | 7 | 7 | Drugs and targets |
| DABIGATRAN | CHEMBL48361 | Small molecule | Approval | TTD | 7 | 6 | 5 | Drugs and targets |
| SIMVASTATIN | CHEMBL1064 | Small molecule | Approval | DailyMed | 115 | 3 | 2 | Drugs and targets |
| VALSARTAN | CHEMBL1069 | Small molecule | Approval | DailyMed | 6 | 2 | 2 | Drugs and targets |
1 to 10 of 228
See all 228 drugsTargets275
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB1 | Adrenergic receptor | 12 | Adrenergic receptor agonist; Adrenergic receptor antagonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 7 | Adrenergic receptor agonist; Adrenergic receptor antagonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist | Approval | https://conductscience.org/library/genes/154 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 7 | Type-1 angiotensin II receptor antagonist | Approval | https://conductscience.org/library/genes/185 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 6 | HMG-CoA reductase inhibitor | Approval | https://conductscience.org/library/genes/3156 | Drugs and targets |
| P2RY12 | P2Y purinoceptor 12 | 6 | Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator | Approval | https://conductscience.org/library/genes/64805 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 5 | Angiotensin-converting enzyme inhibitor | Approval | https://conductscience.org/library/genes/1636 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 5 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 5 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 5 | Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/146 | Drugs and targets |
| F10 | Coagulation factor X | 5 | Coagulation factor X inhibitor | Approval | https://conductscience.org/library/genes/2159 | Drugs and targets |
1 to 10 of 275
See all 275 targetsTrials262
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 21 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03817463 | A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes | 327,624 | 2024-09-23 | Diabetes Mellitus, Type 2 | DEXTROSE, EMPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05321810 | Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation | 193,565 | 2024-01-11 | Non-valvular Atrial Fibrillation | APIXABAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05438888 | Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data | 77,814 | 2024-05-20 | Non-valvular Atrial Fibrillation | APIXABAN, WARFARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03254134 | Comparative Effectiveness and Safety Between Warfarin and Dabigatran | 22,490 | 2019-07-09 | Atrial Fibrillation | DABIGATRAN, WARFARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02270242 | Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention | Phase 4 | 9,006 | 2020-08-19 | Cardiovascular Disease, Interventional Cardiology | ASPIRIN, TICAGRELOR | Its record names the disease | ClinicalTrials.gov |
| NCT01742117 | Tailored Antiplatelet Therapy Following PCI | Phase 4 | 5,276 | 2021-11-09 | Coronary Artery Disease, Acute Coronary Syndrome, Stenosis | CLOPIDOGREL, TICAGRELOR | Its record names the disease | ClinicalTrials.gov |
| NCT00059332 | Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial | Phase 3 | 1,700 | 2015-08-21 | Cerebrovascular Accident | MAGNESIUM SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02240667 | Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF) | 1,506 | 2019-04-19 | Atrial Fibrillation | DABIGATRAN ETEXILATE, VITAMIN K | Its record names the disease | ClinicalTrials.gov | |
| NCT02943785 | Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) | Phase 3 | 1,426 | 2022-03-24 | Atrial Fibrillation | EDOXABAN | Its record names the disease | ClinicalTrials.gov |
| NCT03187197 | Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation | 1,315 | 2020-02-24 | Atrial Fibrillation | DABIGATRAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 262
See all 262 trialsComparisons in its trials90
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause | 1,371 of 163,812 | 2,524 of 163,812 | 327,624 | NCT03817463 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 18 Months: Secondary Prevention (Balanced) Cohorts | 1,095 of 7,796 | 1,272 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 6 Months: Secondary Prevention (Balanced) Cohorts | 2,061 of 7,796 | 2,393 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 0 Month: Secondary Prevention (Balanced) Cohorts | 7,796 of 7,796 | 11,601 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 18 Months: Secondary Prevention (Balanced) Cohorts | 1,110 of 7,796 | 1,283 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 24 Months: Secondary Prevention (Balanced) Cohorts | 850 of 7,796 | 1,028 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 0 Month: Secondary Prevention (Balanced) Cohorts | 7,796 of 7,796 | 11,601 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 24 Months: Secondary Prevention (Balanced) Cohorts | 845 of 7,796 | 1,024 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 12 Months: Secondary Prevention (Balanced) Cohorts | 1,426 of 7,796 | 1,670 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 12 Months: Secondary Prevention (Balanced) Cohorts | 1,448 of 7,796 | 1,685 of 11,601 | 19,397 | NCT05321810 | Trial comparisons |
1 to 10 of 90
See all 90 comparisons in its trialsPapers from its trials354
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005098
GET https://conductscience.org/api/diseases/v1/MONDO_0005098/drugs?page=2